Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00902486 · ClinicalTrials.gov registry record · Phase 2

INCB028050 Compared to Background Therapy in Patients With Active Rheumatoid Arthritis (RA) With Inadequate Response to Disease Modifying Anti-Rheumatic Drugs

A Phase 2 study of Rheumatoid Arthritis, sponsored by Incyte Corporation.

Completed
Registry status
Phase 2
Development phase
127
Enrollment target
20
Study locations

NCT00902486 is a Phase 2 study of Rheumatoid Arthritis that has completed, run by Incyte Corporation. The registered enrollment target is 127 participants, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (97% lower). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00902486, a Phase 2 study of Rheumatoid Arthritis, has completed, sponsored by Incyte Corporation.

COMPLETED
Registry status
Phase 2
Development phase
127 participants
Enrollment target
20
Study locations

Study Summary

This was a randomized, double blind, placebo controlled, dose ranging, parallel group study. Participants who had active rheumatoid arthritis (RA) who had inadequate response to any disease modifying anti-rheumatic drug (DMARD) therapy including biologics were enrolled. Screening evaluations were performed within approximately 28 days of randomization. The duration of the study was 6 months with the primary endpoint assessed at 3 months. Eligible participants were randomly assigned to one of three doses (4, 7 or 10 mg QD) of INCB028050 (Baricitinib) or placebo.

Conditions Studied

Rheumatoid Arthritis

Interventions

  • DRUG Placebo
  • DRUG INCB028050

Study Locations (20)

Florida

  • - Aventura
  • - Daytona Beach
  • - Gainesville
  • - Lake Mary
  • - Naples
  • - Palm Harbor
  • - Sarasota

California

  • - Palm Desert
  • - Santa Maria
  • - Santa Monica
  • - Westlake Village
  • - Whittier

Arizona

  • - Paradise Valley
  • - Peoria
  • - Phoenix

Alabama

  • - Birmingham

Colorado

  • - Denver

Illinois

  • - Springfield

Indiana

  • - South Bend

Kansas

  • - Wichita

Trial Details

FieldValue
Enrollment Target 127 participants
Start Date 2009-05
Est. Completion 2010-07
Phase Phase 2

Sponsor

Incyte Corporation

239 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00902486

The ClinicalTrials.gov registry entry for NCT00902486 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 127 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (97% lower). The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00902486 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Florida, California, Arizona.

Frequently Asked Questions

What is clinical trial NCT00902486 about?

NCT00902486 is a clinical study titled "INCB028050 Compared to Background Therapy in Patients With Active Rheumatoid Arthritis (RA) With Inadequate Response to Disease Modifying Anti-Rheumatic Drugs". This was a randomized, double blind, placebo controlled, dose ranging, parallel group study. Participants who had active rheumatoid arthritis (RA) who had inadequate response to any disease modifying anti-rheumatic drug (DMARD) therapy including biologics were enrolled. Screening evaluations were pe...

What is the current status of trial NCT00902486?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 127 participants. The study started on 2009-05. Estimated completion is 2010-07.

What conditions does trial NCT00902486 study?

This clinical trial studies the following conditions: Rheumatoid Arthritis.

What interventions are being tested in trial NCT00902486?

The interventions under investigation include: Placebo (DRUG), INCB028050 (DRUG).

Who is sponsoring clinical trial NCT00902486?

This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00902486 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Rheumatoid Arthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Rheumatoid Arthritis

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.